Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction

Ki Bum Won, Seung Ho Hur, Chang Wook Nam, Soe Hee Ann, Gyung Min Park, Sang Gon Lee, Hyo Eun Kim, Yun Kyeong Cho, Hyuck Jun Yoon, Hyoung Seob Park, Hyungseop Kim, Seongwook Han, Myung Ho Jeong, Young Keun Ahn, Seung-Woon Rha, Chong Jin Kim, Myeong Chan Cho, Hyo Soo Kim, Shung Chull Chae, Kee Sik KimYoung Jo Kim, Kwon Bae Kim, Philip Barter

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The phenomenon of obesity paradox after acute myocardial infarction (AMI) has been reported under strong recommendation of statin therapy. However, the impact of statin therapy on this paradox has not been investigated. This study investigated the impact of statin therapy on 1-year mortality according to obesity after AMI. A total of 2745 AMI patients were included from the Korea Acute Myocardial Infarction Registry after 1:4 propensity score matching analysis (n = 549 for nonstatin group and n = 2196 for statin group). Primary and secondary outcomes were all-cause and cardiac death, respectively. During 1-year follow-up, the incidence of all-cause (8.4% vs 3.7%) and cardiac (6.2% vs 2.3%) death was higher in nonstatin group than in statin (P < .001, respectively). In nonstatin group, the incidence of all-cause (7.2% vs 9.0%) and cardiac (5.5% vs 6.5%) death did not differ significantly between obese and nonobese patients. However, in statin group, obese patients had lower 1-year rate of all-cause (1.7% vs 4.8%) and cardiac (1.2% vs 2.9%) death (P < .05, respectively), and lower cumulative rates by Kaplan-Meier analysis of all-cause and cardiac death compared with nonobese patients (log-rank P < .05, respectively). The overall risk of all-cause death was significantly lower in obese than in nonobese patients only in statin group (hazard ratio: 0.35; P = .001). After adjusting for confounding factors, obesity was independently associated with decreased risk of all-cause death in statin group. In conclusion, the greater benefit of statin therapy for survival in obese patients is further confirmation of the obesity paradox after AMI.

Original languageEnglish
Article numbere7180
JournalMedicine (United States)
Volume96
Issue number35
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Obesity
Myocardial Infarction
Cause of Death
Therapeutics
Propensity Score
Incidence
Kaplan-Meier Estimate
Korea
Registries
Survival

Keywords

  • acute myocardial infarction
  • mortality
  • obesity
  • statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction. / Won, Ki Bum; Hur, Seung Ho; Nam, Chang Wook; Ann, Soe Hee; Park, Gyung Min; Lee, Sang Gon; Kim, Hyo Eun; Cho, Yun Kyeong; Yoon, Hyuck Jun; Park, Hyoung Seob; Kim, Hyungseop; Han, Seongwook; Jeong, Myung Ho; Ahn, Young Keun; Rha, Seung-Woon; Kim, Chong Jin; Cho, Myeong Chan; Kim, Hyo Soo; Chae, Shung Chull; Kim, Kee Sik; Kim, Young Jo; Kim, Kwon Bae; Barter, Philip.

In: Medicine (United States), Vol. 96, No. 35, e7180, 01.09.2017.

Research output: Contribution to journalArticle

Won, KB, Hur, SH, Nam, CW, Ann, SH, Park, GM, Lee, SG, Kim, HE, Cho, YK, Yoon, HJ, Park, HS, Kim, H, Han, S, Jeong, MH, Ahn, YK, Rha, S-W, Kim, CJ, Cho, MC, Kim, HS, Chae, SC, Kim, KS, Kim, YJ, Kim, KB & Barter, P 2017, 'Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction', Medicine (United States), vol. 96, no. 35, e7180. https://doi.org/10.1097/MD.0000000000007180
Won, Ki Bum ; Hur, Seung Ho ; Nam, Chang Wook ; Ann, Soe Hee ; Park, Gyung Min ; Lee, Sang Gon ; Kim, Hyo Eun ; Cho, Yun Kyeong ; Yoon, Hyuck Jun ; Park, Hyoung Seob ; Kim, Hyungseop ; Han, Seongwook ; Jeong, Myung Ho ; Ahn, Young Keun ; Rha, Seung-Woon ; Kim, Chong Jin ; Cho, Myeong Chan ; Kim, Hyo Soo ; Chae, Shung Chull ; Kim, Kee Sik ; Kim, Young Jo ; Kim, Kwon Bae ; Barter, Philip. / Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction. In: Medicine (United States). 2017 ; Vol. 96, No. 35.
@article{1b5b945cdff44b11971ee7fe1f7577b5,
title = "Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction",
abstract = "The phenomenon of obesity paradox after acute myocardial infarction (AMI) has been reported under strong recommendation of statin therapy. However, the impact of statin therapy on this paradox has not been investigated. This study investigated the impact of statin therapy on 1-year mortality according to obesity after AMI. A total of 2745 AMI patients were included from the Korea Acute Myocardial Infarction Registry after 1:4 propensity score matching analysis (n = 549 for nonstatin group and n = 2196 for statin group). Primary and secondary outcomes were all-cause and cardiac death, respectively. During 1-year follow-up, the incidence of all-cause (8.4{\%} vs 3.7{\%}) and cardiac (6.2{\%} vs 2.3{\%}) death was higher in nonstatin group than in statin (P < .001, respectively). In nonstatin group, the incidence of all-cause (7.2{\%} vs 9.0{\%}) and cardiac (5.5{\%} vs 6.5{\%}) death did not differ significantly between obese and nonobese patients. However, in statin group, obese patients had lower 1-year rate of all-cause (1.7{\%} vs 4.8{\%}) and cardiac (1.2{\%} vs 2.9{\%}) death (P < .05, respectively), and lower cumulative rates by Kaplan-Meier analysis of all-cause and cardiac death compared with nonobese patients (log-rank P < .05, respectively). The overall risk of all-cause death was significantly lower in obese than in nonobese patients only in statin group (hazard ratio: 0.35; P = .001). After adjusting for confounding factors, obesity was independently associated with decreased risk of all-cause death in statin group. In conclusion, the greater benefit of statin therapy for survival in obese patients is further confirmation of the obesity paradox after AMI.",
keywords = "acute myocardial infarction, mortality, obesity, statins",
author = "Won, {Ki Bum} and Hur, {Seung Ho} and Nam, {Chang Wook} and Ann, {Soe Hee} and Park, {Gyung Min} and Lee, {Sang Gon} and Kim, {Hyo Eun} and Cho, {Yun Kyeong} and Yoon, {Hyuck Jun} and Park, {Hyoung Seob} and Hyungseop Kim and Seongwook Han and Jeong, {Myung Ho} and Ahn, {Young Keun} and Seung-Woon Rha and Kim, {Chong Jin} and Cho, {Myeong Chan} and Kim, {Hyo Soo} and Chae, {Shung Chull} and Kim, {Kee Sik} and Kim, {Young Jo} and Kim, {Kwon Bae} and Philip Barter",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MD.0000000000007180",
language = "English",
volume = "96",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "35",

}

TY - JOUR

T1 - Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction

AU - Won, Ki Bum

AU - Hur, Seung Ho

AU - Nam, Chang Wook

AU - Ann, Soe Hee

AU - Park, Gyung Min

AU - Lee, Sang Gon

AU - Kim, Hyo Eun

AU - Cho, Yun Kyeong

AU - Yoon, Hyuck Jun

AU - Park, Hyoung Seob

AU - Kim, Hyungseop

AU - Han, Seongwook

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Rha, Seung-Woon

AU - Kim, Chong Jin

AU - Cho, Myeong Chan

AU - Kim, Hyo Soo

AU - Chae, Shung Chull

AU - Kim, Kee Sik

AU - Kim, Young Jo

AU - Kim, Kwon Bae

AU - Barter, Philip

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The phenomenon of obesity paradox after acute myocardial infarction (AMI) has been reported under strong recommendation of statin therapy. However, the impact of statin therapy on this paradox has not been investigated. This study investigated the impact of statin therapy on 1-year mortality according to obesity after AMI. A total of 2745 AMI patients were included from the Korea Acute Myocardial Infarction Registry after 1:4 propensity score matching analysis (n = 549 for nonstatin group and n = 2196 for statin group). Primary and secondary outcomes were all-cause and cardiac death, respectively. During 1-year follow-up, the incidence of all-cause (8.4% vs 3.7%) and cardiac (6.2% vs 2.3%) death was higher in nonstatin group than in statin (P < .001, respectively). In nonstatin group, the incidence of all-cause (7.2% vs 9.0%) and cardiac (5.5% vs 6.5%) death did not differ significantly between obese and nonobese patients. However, in statin group, obese patients had lower 1-year rate of all-cause (1.7% vs 4.8%) and cardiac (1.2% vs 2.9%) death (P < .05, respectively), and lower cumulative rates by Kaplan-Meier analysis of all-cause and cardiac death compared with nonobese patients (log-rank P < .05, respectively). The overall risk of all-cause death was significantly lower in obese than in nonobese patients only in statin group (hazard ratio: 0.35; P = .001). After adjusting for confounding factors, obesity was independently associated with decreased risk of all-cause death in statin group. In conclusion, the greater benefit of statin therapy for survival in obese patients is further confirmation of the obesity paradox after AMI.

AB - The phenomenon of obesity paradox after acute myocardial infarction (AMI) has been reported under strong recommendation of statin therapy. However, the impact of statin therapy on this paradox has not been investigated. This study investigated the impact of statin therapy on 1-year mortality according to obesity after AMI. A total of 2745 AMI patients were included from the Korea Acute Myocardial Infarction Registry after 1:4 propensity score matching analysis (n = 549 for nonstatin group and n = 2196 for statin group). Primary and secondary outcomes were all-cause and cardiac death, respectively. During 1-year follow-up, the incidence of all-cause (8.4% vs 3.7%) and cardiac (6.2% vs 2.3%) death was higher in nonstatin group than in statin (P < .001, respectively). In nonstatin group, the incidence of all-cause (7.2% vs 9.0%) and cardiac (5.5% vs 6.5%) death did not differ significantly between obese and nonobese patients. However, in statin group, obese patients had lower 1-year rate of all-cause (1.7% vs 4.8%) and cardiac (1.2% vs 2.9%) death (P < .05, respectively), and lower cumulative rates by Kaplan-Meier analysis of all-cause and cardiac death compared with nonobese patients (log-rank P < .05, respectively). The overall risk of all-cause death was significantly lower in obese than in nonobese patients only in statin group (hazard ratio: 0.35; P = .001). After adjusting for confounding factors, obesity was independently associated with decreased risk of all-cause death in statin group. In conclusion, the greater benefit of statin therapy for survival in obese patients is further confirmation of the obesity paradox after AMI.

KW - acute myocardial infarction

KW - mortality

KW - obesity

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=85028731213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028731213&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000007180

DO - 10.1097/MD.0000000000007180

M3 - Article

C2 - 28858077

AN - SCOPUS:85028731213

VL - 96

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 35

M1 - e7180

ER -